Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DLReady Certification Awarded for Synergy 2 and Synergy HT Multi-Detection Microplate Readers

Published: Wednesday, November 08, 2006
Last Updated: Wednesday, November 08, 2006
Bookmark and Share
The DLR Assay System provides quantitation of firefly and Renilla luciferase reporters in transfected cells.

BioTek Instruments has received DLReady™ certification for dual-luciferase assays on both the Synergy™2 and Synergy™ HT multi-detection microplate readers.

Awarded by Promega Corporation, this certification validates an instrument to the highest performance levels and standards for the Dual-Luciferase® Reporter (DLR™) Assay System.

The DLR Assay System is designed to provide quantitation of firefly and Renilla luciferase reporters in transfected cells or in cell-free transcription/translation reactions.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioTek Recognized with 5x5x5 Award Again
BioTek receives the Award at the 9th annual awards ceremony on Thursday, September 15, 2011.
Saturday, September 17, 2011
BioTek Instruments Announces Establishment of Korean Office
Managed by Mr. Yunki Kyung, the new direct sales and service organization will focus on growing BioTek's brand and expanding direct service and application support for our growing customer base in South Korea.
Tuesday, March 01, 2011
BioTek Announces New Applications and Business Development Manager in Canada
Dr Charles Amirmansour is responsible for supporting BioTek's technical and new business activities with Fisher Scientific Canada.
Monday, February 28, 2011
BioTek Instruments Continues Global Expansion with Opening of Singapore Office
The new office will support and further increase the growth experienced by BioTek in the Asia Pacific region.
Friday, November 30, 2007
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!